Sanjiv Patel

CEO Sanjiv Patel sold 48.2K shares of RLAY at $19.58 on 2026-07-07 via pre-arranged 10b5-1 plan; still holds 615.9K shares post-transaction.

Sanjiv Patel (President and CEO) executed a sale of 48,199 shares at $19.58 under a 10b5-1 trading plan adopted on 2025-10-30, reducing holdings from 664,097 to 615,898 shares. The sale occurred as the stock trades at $19.63, near its 52-week high of $20.20, though the current 30-day and 90-day changes of +43.7% and +30.9% reflect recent strength. Patel's prior trades at RLAY show mixed outcomes: his five previous sells at this ticker yielded 90-day average returns that ranged from -19.2% to -39.2%, suggesting his prior RLAY exits preceded subsequent declines. The company remains unprofitable (net income of $-73,291,000.00 in the latest full fiscal year) despite strong revenue growth of +53.4% year-over-year, creating a backdrop where the timing of insider liquidity events warrants attention, though the scheduled nature of the 10b5-1 plan means this transaction was predetermined rather than discretionary.

CEO Patel sells 215,506 shares (19.6% of holdings) across 2 transactions for $818,399.50 at $3.80–$3.85; stock down 63.5% from 52-week high.

Patel Sanjiv, President and CEO of Relay Therapeutics, executed 2 separate sales totaling 215,506 shares (215.5K shares) for $818,399.50 on February 11 and February 13, 2025, reducing his stake by 19.6% from 1,098,595 shares to 883,089 shares. The sales occurred at $3.85 and $3.70 per share (blended average $3.80), compared to the current price of $3.96—within the stock's recent range but -63.5% below its 52-week high of $10.84. Across his cross-ticker open-market history, Patel has executed 5 prior sells with an average 90-day well-timed rate of 100.00% and an average 90-day return of -31.5%, indicating a pattern of selling before subsequent declines. At RLAY specifically, his 2 measurable prior sales (July 2024) both posted negative 90-day returns (-31.8% and -31.2%), consistent with this pattern. Against this backdrop, a CEO liquidating roughly one-fifth of his holdings in a company that reported unprofitable operations (net income of $-88,105,000.00 for the latest full fiscal year) and whose stock has declined 22.4% in the past 90 days and 8.9% in the past 30 days warrants investor attention, particularly given the company's reliance on its $10,007,000.00 quarterly revenue and the demonstrated historical tendency of this insider's sales to precede further price weakness.

RLAY CEO Patel sells 375,000 shares for $1.8M across 3 trades (Jan 21-23) via pre-arranged 10b5-1 plan

Patel Sanjiv, President and CEO, executed 3 separate sales totaling 375,000 shares for $1.8M between January 21-23 at prices ranging from $4.52 to $4.80 (blended average $4.70). This represents a 65.3% reduction in his holdings, from 574,548 shares to 199,548 shares. The sales are part of a pre-arranged 10b5-1 trading plan adopted on 2024-08-07, meaning the transactions were scheduled in advance rather than discretionary. The scale of the position reduction—approximately two-thirds of his stake—is material, though the plan-based nature indicates the timing and amounts were predetermined.

RLAY CEO Patel sells 86,706 shares across 2 transactions for $790.9K at $9.12 avg; stock now $8.22

Sanjiv Patel, President and CEO, executed 2 separate sales totaling 86,706 shares for $790,923.42 at a blended average price of $9.12 on July 25-26, 2024. The sales reduced his holdings from 852,836 shares to 766,130 shares, a -10.2% reduction. RLAY is an unprofitable biotech company with $10.0M quarterly revenue and a net loss of $81.4M in its most recent full year, though annual revenue grew 1749.8%. The stock currently trades at $8.22, 34.8% below its 52-week high of $12.60 but up 26.1% over both the prior 30 and 90 days. The CEO sold at prices $9.07–$9.16, above the current $8.22 level, which occurred after a recent recovery phase in the stock.